GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bioporto AS (OCSE:BIOPOR) » Definitions » Institutional Ownership

Bioporto AS (OCSE:BIOPOR) Institutional Ownership : 0.22% (As of May. 07, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Bioporto AS Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bioporto AS's institutional ownership is 0.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bioporto AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bioporto AS's Float Percentage Of Total Shares Outstanding is 0.00%.


Bioporto AS Institutional Ownership Historical Data

The historical data trend for Bioporto AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioporto AS Institutional Ownership Chart

Bioporto AS Historical Data

The historical data trend for Bioporto AS can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Institutional Ownership 0.22 0.29 0.35 0.31 0.28 0.28 0.19 0.19 0.23 0.22

Bioporto AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Bioporto AS Business Description

Traded in Other Exchanges
Address
Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.

Bioporto AS Headlines

No Headlines